Get started
Keyword

thalidomide

Description: Thalidomide is an immunomodulatory drug used in treating conditions such as multiple myeloma and known to cause severe birth defects.
Wikidata ID: wiki/Q203174
OpenAlex ID: keywords/thalidomide
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 · Seema Singhal, Jayesh Mehta, et al. · New England Journal of Medicine · 2,580
PDF
Thalidomide is an inhibitor of angiogenesis.
1994 · R J D'Amato, M S Loughnan, et al. · Proceedings of the National Academy of Sciences · 2,457
Multiple Myeloma
2011 · Antonio Palumbo, Kenneth Anderson · New England Journal of Medicine · 2,337
Improved survival in multiple myeloma and the impact of novel therapies
2007 · Shaji K. Kumar, S. Vincent Rajkumar, et al. · Blood · 2,241
PDF
Multiple myeloma
2000 · Noopur Raje, Kenneth C. Anderson · Current Treatment Options in Oncology · 2,164
Identification of a Primary Target of Thalidomide Teratogenicity
2010 · Takumi Ito, Hideki Ando, et al. · Science · 2,108
Multiple Myeloma
2004 · Robert A. Kyle, S. Vincent Rajkumar · New England Journal of Medicine · 1,296
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
1991 · E P Sampaio, E N Sarno, et al. · The Journal of Experimental Medicine · 1,192
PDF
Thalidomide and Congenital Abnormalities
1961 · W.G. Mcbride · The Lancet · 1,146
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
2014 · Eric S. Fischer, Kerstin Böhm, et al. · Nature · 1,106
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.
1993 · A L Moreira, E P Sampaio, et al. · The Journal of Experimental Medicine · 1,045
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
2019 · Philippe Moreau, Michel Attal, et al. · The Lancet · 969
PDF
American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
2007 · Gary H. Lyman, Alok A. Khorana, et al. · Journal of Clinical Oncology · 952
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
2001 · Faith E. Davies, Noopur Raje, et al. · Blood · 913
Thalidomide‐induced teratogenesis: History and mechanisms
2015 · Neil Vargesson · Birth Defects Research Part C Embryo Today Reviews · 912
PDF
NF-κB as a Therapeutic Target in Multiple Myeloma
2002 · Teru Hideshima, Dharminder Chauhan, et al. · Journal of Biological Chemistry · 893
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
2000 · Teru Hideshima, Dharminder Chauhan, et al. · Blood · 876
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial
2007 · Thierry Facon, Jean Yves Mary, et al. · The Lancet · 869
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
2005 · S. Vincent Rajkumar, Emily Blood, et al. · Journal of Clinical Oncology · 866
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
2015 · Jan Krönke, Emma C. Fink, et al. · Nature · 846
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
2007 · A Palumbo, S V Rajkumar, et al. · Leukemia · 843
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
2019 · Renata Zajączkowska, Magdalena Kocot-Kępska, et al. · International Journal of Molecular Sciences · 831
PDF
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
2012 · Pieter Sonneveld, Ingo G.H. Schmidt-Wolf, et al. · Journal of Clinical Oncology · 826
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
2010 · Michele Cavo, Paola Tacchetti, et al. · The Lancet · 819
Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge
2007 · Kathy J. Jenkins, Adolfo Correa, et al. · Circulation · 819
Works count: 18,710
Citation count: 338,000
Year
Topic
Type